Onishi, Yukiko http://orcid.org/0000-0003-1180-5982
Oura, Tomonori http://orcid.org/0000-0003-0872-8576
Takeuchi, Masakazu http://orcid.org/0000-0003-3176-3118
Clinical trials referenced in this document:
Documents that mention this clinical trial
Treatment Satisfaction and Quality of Life with Tirzepatide Versus Dulaglutide Among Japanese Patients with Type 2 Diabetes: Exploratory Evaluation of the SURPASS J-mono Trial
https://doi.org/10.1007/s13300-023-01485-3
Metabolic Abnormalities Following Tirzepatide Monotherapy in Japanese Patients with Type 2 Diabetes: A Phase 3 SURPASS J-mono Post Hoc Analysis
https://doi.org/10.1007/s13300-024-01534-5
Funding for this research was provided by:
Eli Lilly Japan
Mitsubishi Tanabe Pharma Corporation
Eli Lilly and Company
Article History
Received: 29 October 2023
Accepted: 15 January 2024
First Online: 4 February 2024
Declarations
:
: All authors declare funding support for this study and manuscript from Eli Lilly Japan K.K. and Mitsubishi Tanabe Pharma Corporation. Yukiko Onishi reports receiving personal fees from Eli Lilly and Company, MSD, Novartis, Novo Nordisk, and Sumitomo Pharma outside the submitted work. Tomonori Oura and Masakazu Takeuchi are employees of Eli Lilly Japan and minor shareholders of Eli Lilly and Company.
: The study protocol was approved by independent ethical review boards at each participating site (protocol and list of ethical review boards were previously published in the primary manuscript [CitationRef removed]). The study was conducted in accordance with the Declaration of Helsinki in 1995 (as revised in Fortaleza, Brazil, October 2013) and the Council for International Organizations of Medical Sciences International Ethical Guidelines. All participants provided written informed consent prior to participating in the trial.